[Form 4] LifeMD, Inc. Insider Trading Activity

Rhea-AI Filing Summary

LifeMD director Joan LaRovere reported a non‑derivative grant of 22,365 restricted shares of common stock acquired on 10/06/2025, increasing her beneficial holdings to 107,050 shares. The shares were granted at a price of $0, indicating they are restricted stock rather than a purchased award.

The grant carries a vesting condition: the restricted shares vest on June 1, 2026. This filing records a direct ownership change by a company insider; no options, conversions, or derivative instruments were reported.

Positive

• 22,365 restricted shares granted, aligning director compensation with shareholder outcomes
• Beneficial ownership increased to 107,050 shares, strengthening insider stake
• Clear vesting date of June 1, 2026 provides transparency on timing of dilution/ownership change

Negative

• None.

Insights

Corporate Governance Analyst

Director received restricted shares that vest mid‑2026, modestly increasing insider ownership.

The transaction is a standard restricted stock grant: 22,365 shares were recorded as acquired at $0, which typically reflects compensation rather than a market purchase. Such grants align director incentives with shareholder value by delaying full ownership until the vesting date.

Key dependencies include continued service until the vesting date of June 1, 2026 and any plan terms governing forfeiture. Monitor insider holdings and future grants for changes in governance incentives over the next 6–12 months.

Equity Compensation Specialist

The award structure is restricted stock with a clear vesting date; no derivatives or cash exercise are involved.

Because the reported price is $0, this is a grant rather than an exercised option, and the filing shows direct beneficial ownership rising to 107,050 shares after the grant. No derivative securities were reported in Table II.

Investor‑relevant items to watch include whether the shares fully vest on June 1, 2026 and if additional grants are made under the same plan within the next year, which could affect insider share concentration.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAROVERE JOAN

(Last) (First) (Middle)

C/O LIFEMD

236 FIFTH AVENUE, SUITE 400

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/06/2025		A		22,365	A	$0(1)	107,050	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The grant of restricted shares vests on June 1, 2026.

	/s/ Joan LaRovere	10/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for LifeMD (LFMD)?

The Form 4 was filed by Joan LaRovere, who is identified as a director of LifeMD.

What transaction did Joan LaRovere report for LFMD?

Ms. LaRovere reported the acquisition of 22,365 restricted shares of common stock, recorded as acquired on 10/06/2025.

How many shares does Joan LaRovere beneficially own after the transaction?

Following the reported transaction, her beneficial ownership is 107,050 shares.

What price was reported for the shares acquired in the Form 4?

The reported price is $0, indicating the shares were granted as restricted stock rather than purchased.

When do the restricted shares vest?

The restricted shares are scheduled to vest on June 1, 2026.